AI Article Synopsis
- - The study explores the concept of remission for severe asthma patients on biological treatments, aiming to establish clearer criteria for successful remission which typically includes reduced steroid use, fewer exacerbations, minimal symptoms, and improved lung function.
- - In a cross-sectional analysis of 39 adults with severe asthma, the research found that a significant percentage met some remission criteria, but there was considerable variability in outcomes depending on the specific criteria used.
- - The findings suggest that while achieving clinical remission is possible for patients using biological therapies, there is a need for more consistent and clearly defined criteria to effectively measure and compare remission across different patients.
Article Abstract
Background: The concept of remission on biological treatment has been suggested as a therapeutic target for patients with severe asthma, composed of 1. no chronic use of systemic steroids, 2. no exacerbations, 3. minimal symptoms, and 4. optimized lung function, for a significant time. However, the criteria for remission are not clearly defined.
Objective: Our objective was to compare different criteria for remission in subjects receiving biologicals for severe asthma.
Methods: A cross-sectional study of adult subjects who receive a stable regimen of a biological for severe asthma for at least 6-months. We compared the proportion of subjects who fulfilled different specific criteria in the four domains, as well as those who achieved different composite outcome measures of clinical remission.
Results: Of 39 subjects, 28 were females (71.8%), mean age 60.4. Twelve were current or past smokers (30.8%). Twelve had prior different biological treatment (30.8%), and 3/39 had more than one previous treatment (7.7%). Current biological included mepolizumab 12/39 (30.8%), dupilumab 11/39 (28.2%), benralizumab 10/39 (25.6%), omalizumab 5/39 (12.8%), reslizumab 1/39 (2.6%). Different specific criteria were achieved in 39-80% of subjects, being highest for no chronic steroid use and lowest for symptoms control and lung function. Overall remission was obtained by 20-41%, depending on definition, with significant variability in agreement between different sets of remission criteria (Cohen's kappa 0.33-0.89).
Conclusion: Clinical remission is achievable in real-world severe asthmatics on biological therapies. The core criteria for remission should be better defined.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rmed.2024.107528 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between vitamin D status at 3 years and eosinophilic asthma in 6-year-old children with a history of severe bronchiolitis.
Thorax
January 2025
Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
The association between early childhood serum 25-hydroxyvitamin D (25(OH)D) and eosinophilic asthma remains unclear. We investigated this association using multicentre prospective data from 584 children with a history of bronchiolitis requiring hospitalisation (high-risk population). Low serum 25(OH)D levels (<20 ng/mL) were associated with increased odds of developing eosinophilic asthma (adjusted OR 2.
View Article and Find Full Text PDFBackground therapy in severe asthma on monoclonal antibody treatment in Real Life.
Respir Med
January 2025
S.C. Pneumologia, ASL2 Savonese, Savona, Italy. Electronic address:
Background: Global Initiative for Asthma (GINA) recently recommends clinicians to reduce inhaled corticosteroid doses in patients with severe asthma who respond positively to monoclonal antibodies (MAbs).
Objective: As we operated this reduction even before the document, we analysed our cohort of subjects on treatment with a MAbs for at least 24 months.
Methods: Data stored in our electronic archive and at the 6-month follow-up (FU) were registered and patients' adherence to asthma therapy was derived by electronic pharmacy claim database.
Health effects associated with ozone in China: A systematic review.
Environ Pollut
January 2025
Department of Environmental Science and Engineering, Fudan University, Shanghai 200438, China. Electronic address:
As the ozone (O) pollution becomes severe in China, it poses a threat to human health. Currently, studies on the impacts of O on different regions and groups are limited. This review systematically summarizes the relationship between O pollution and mortality and morbidity across the nation, regions, and cities in China, with a focus on the regional and group-specific studies.
View Article and Find Full Text PDFIn severe asthma with an eosinophilic phenotype, depemokimab improved exacerbations, but not quality of life, at 52 wk.
Ann Intern Med
January 2025
Austin Hospital and University of Melbourne, Melbourne, Victoria, Australia (C.F.M.).
GIM/FP/GP: [Formula: see text] Allerg & Immunol: [Formula: see text] Pulmonology: [Formula: see text].
View Article and Find Full Text PDFBurden of Infections in Early Life and Risk of Infections and Systemic Antibiotics Use in Childhood.
JAMA Netw Open
January 2025
Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
Importance: A high infection burden in early childhood is common and a risk factor for later disease development. However, longitudinal birth cohort studies investigating early-life infection burden and later risk of infection and antibiotic episodes are lacking.
Objective: To investigate whether early-life infection burden is associated with a later risk of infection and systemic antibiotic treatment episodes in childhood.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!